New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.

Sahil Parikh, MD, director of endovascular services, New York-Presbyterian, explains details from the big-data REAL-PE study comparing mechanical thrombectomy to ultrasound assisted catheter thrombolysis.

Major complications are rare during percutaneous coronary intervention. When they do occur, however, the in-hospital mortality rate is relatively high. 

Trainees interested in interventional cardiology will now be able to use the Match program to find the right program for their needs. The move is associated with multiple benefits as well as some key challenges.

Medicare rescinded the provision in the 2024 Medicare Physician Fee Schedule, but the law remains on the books. 

Leadless pacemakers may be an "attractive alternative" to transvenous devices when cardiologists treat older TAVR patients who experience conduction disorders.

HeartFlow is using SCCT 2024 to introduce the world to its updated Plaque Analysis platform. “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment," Chief Medical Officer Campbell Rogers, MD, explained.

The American Society of Nuclear Cardiology explored some key points included in the 2025 Medicare Physician Fee Schedule proposed rule.